JoVE Logo

Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Results
  • Discussion
  • Disclosures
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

Here, we present the methodology for concisely assessing autophagosome marker LC3-II levels in extracellular vesicles (EVs) by immunoblotting. Analysis for LC3-II levels in EVs, autolysosome formation, and omegasome formation suggests the new role of STX6 in the release of LC3-II-positive EVs when autophagosome-lysosome fusion is inhibited.

Abstract

(Macro)autophagy represents a fundamental cellular degradation pathway. In this process, double-membraned vesicles known as autophagosomes engulf cytoplasmic contents, subsequently fusing with lysosomes for degradation. Beyond the canonical role, autophagy-related genes also modulate a secretory pathway involving the release of inflammatory molecules, tissue repair factors, and extracellular vesicles (EVs). Notably, the process of disseminating pathological proteins between cells, particularly in neurodegenerative diseases affecting the brain and spinal cord, underscores the significance of understanding this phenomenon. Recent research suggests that the transactive response DNA-binding protein 43 kDa (TDP-43), a key player in amyotrophic lateral sclerosis and frontotemporal lobar degeneration, is released in an autophagy-dependent manner via EVs enriched with the autophagosome marker microtubule-associated proteins 1A/1B light chain 3B-II (LC3-II), especially when autophagosome-lysosome fusion is inhibited.

To elucidate the mechanism underlying the formation and release of LC3-II-positive EVs, it is imperative to establish an accessible and reproducible method for evaluating both intracellular and extracellular LC3-II-positive vesicles. This study presents a detailed protocol for assessing LC3-II levels via immunoblotting in cellular and EV fractions obtained through differential centrifugation. Bafilomycin A1 (Baf), an inhibitor of autophagosome-lysosome fusion, serves as a positive control to enhance the levels of intracellular and extracellular LC3-II-positive vesicles. Tumor susceptibility gene 101 (TSG101) is used as a marker for multivesicular bodies. Applying this protocol, it is demonstrated that siRNA-mediated knockdown of syntaxin-6 (STX6), a genetic risk factor for sporadic Creutzfeldt-Jakob disease, augments LC3-II levels in the EV fraction of cells treated with Baf while showing no significant effect on TSG101 levels. These findings suggest that STX6 may negatively regulate the extracellular release of LC3-II via EVs, particularly under conditions where autophagosome-lysosome fusion is impaired. Combined with established methods for evaluating autophagy, this protocol provides valuable insights into the role of specific molecules in the formation and release of LC3-II-positive EVs.

Introduction

Transactivation response DNA-binding protein 43 (TDP-43) is a widely expressed heterogeneous nuclear ribonucleoprotein involved in regulating exon splicing, gene transcription, and mRNA stability, all vital for cell survival1,2. In neurodegenerative conditions like amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD), a nuclear protein TDP-43 abnormally accumulates in the cytoplasm. This shift results in a loss of TDP-43 function in the nucleus and a toxic gain-of-function in the cytoplasm. Pathological accumulation of TDP-43 begins in specific regions of the brain and spinal cord, spreading through these areas in a prion-like fashion, a process closely associated with disease progression3. However, the exact mechanism by which TDP-43 pathology spreads through the brain and spinal cord remains unknown.

TDP-43 is secreted through extracellular vesicles (EVs), and elevated levels of TDP-43 are detected in the plasma and cerebrospinal fluid (CSF) of ALS and FTLD-TDP patients4,5,6. CSF from patients diagnosed with ALS and FTLD induces intracellular mislocalization and aggregation of endogenous TDP-43 in human glioma cells7. Thus, TDP-43 released extracellularly via EVs may mediate the cell-to-cell spreading of TDP-43 pathology.

Autophagy is a well-preserved cellular degradation mechanism that involves the enclosure of unwanted substances within double-membrane vesicles, known as autophagosomes, which are marked by LC3. These autophagosomes fuse with lysosomal-associated membrane protein 1 (LAMP1)-positive lysosomes to form autolysosomes (LC3+/LAMP1+), leading to the degradation of their contents8. Histological analyses indicate that autophagosomes engulfing inclusions accumulate in the neurons of sporadic ALS patients9. Some causal genes of familial ALS and FTLD-TDP are linked to the regulation of autophagy10,11,12. These findings suggest that autophagy is suppressed in ALS and FTLD-TDP patients.

The previous study indicated that TDP-43 is secreted via EVs positive for the autophagosome marker LC3-II when autophagosome-lysosome fusion is inhibited13. Dysregulation of the autophagy-lysosome pathway might cause not only the intracellular accumulation of TDP-43 but also the extracellular release of TDP-43 via EVs14. However, it remains unknown how LC3-II positive EVs are released and how significant this is in the spreading of TDP-43 pathology.

EVs are classified into large EVs (100 to 1000 nm in diameter), which are produced from cell-surface budding, and small EVs (50 to 150 nm in diameter), which are produced from the budding of endosomal membranes toward the interior of the endosome (known as exosomes) and the Golgi apparatus. To separately collect large and small EVs, we perform sequential centrifugation and collect pellets by centrifugation at 20,000 × g and 110,000 × g, respectively. The P1 EV fraction (20,000 × g pellets) is prepared to collect large EVs, and the P2 EV fraction (110,000 × g pellets) is prepared to collect small EVs15. The methodology to assess LC3-II levels in large and small EVs derived from sequential centrifugation by immunoblotting is stable and reproducible16. In addition to analyzing LC3-II levels in EVs, analyzing autolysosome and omegasome formation enhances understanding of how dysregulation of autophagy leads to the release of LC3-II positive EVs. Here, the present study shows the suppressive role of syntaxin 6 (STX6), a SNARE protein, which promotes the movement of transport vesicles to target membranes17, in the release of LC3-II positive EVs when autophagosome-lysosome fusion is inhibited.

Protocol

1. Preparation of the cell, P1, and P2 EV fraction from the cultured medium of HeLa cells

  1. Preparation of the P1 and P2 EV fraction from the cultured medium of HeLa cells
    1. Day 1
      1. Count the cells using a cell counter and seed 1 × 106 cells on a 6 cm plate containing a culture medium composed of DMEM High Glucose, 10% FBS, and 1% penicillin/streptomycin. Incubate the cells at 37 °C with 5% CO2 and controlled humidity for 24 h.
    2. Day 2 (optional)
      1. Prepare 20 µM siRNA solution.
      2. Mix 100 µL of reduced serum medium and 3 µL of siRNA in a low-retention tube to prepare solution A.
      3. Mix 100 µL of reduced serum medium and 5 µL of transfection reagent in a low-retention tube to prepare solution B.
      4. Mix solution A and solution B, then incubate the mixture at room temperature (RT) for 5 min.
      5. Add the mixture of solutions A and B to the medium used for culturing HeLa cells. Incubate the cells at 37 °C with 5% CO2 and controlled humidity for 24 h.
    3. Day 3
      1. Wash the cells with PBS and expose them to 500 µL of 0.25% trypsin and 1 mM EDTA solution at 37 °C with 5% CO2 and controlled humidity for 5 min.
      2. Add 2.5 mL of the culture medium to the cells, and use a Pasteur transfer pipette with a 200 µL pipette tip attached to prepare a single-cell suspension.
      3. Count the cells using a cell counter, and seed 1 × 106 cells on a 10 cm plate. Incubate the cells at 37 °C with 5% CO2 and controlled humidity for 24 h.
        NOTE: It is necessary to prepare at least 1 × 106 cells to collect EVs from the culture medium required for immunoblotting analysis.
    4. Day 4
      1. Prepare culture medium (see step 1.1.1.1) containing either vehicle (DMSO) or 100 nM Bafilomycin A1 (Baf).
      2. Expose the cells to the medium containing either vehicle or 100 nM Baf and incubate them at 37 °C with 5% CO2 and controlled humidity for 24 h.
    5. Day 5
      1. Collect all the culture medium from the 10 cm plate, transfer it into a 15 mL tube, and centrifuge it at 3,000 × g for 10 min at 4 °C to remove cell debris.
        NOTE: The remaining cells in the 10 cm plate will be used in section 1.2.1.
      2. For the isolation of the P1 EV fraction, transfer the supernatant after centrifugation at 3,000 × g into a centrifugation tube, and then centrifuge it at 20,000 × g at 4 °C for 1 h.
      3. For the isolation of the P2 EV fraction, transfer the supernatant after centrifugation at 20,000 × g into an ultracentrifuge tube, and then centrifuge it at 110,000 × g at 4 °C for 1 h.
      4. After wiping off the excess moisture inside the tube with a laboratory wipe, resuspend the remaining pellets in the centrifugation tube in 50 µL of 2x sample buffer [2.5% SDS, 125mM Tris-HCl buffer (pH 6.8), 30% glycerol, 10% 2-mercaptoethanol, 0.4% Bromophenol Blue] to prepare the P1 EV fraction.
      5. Remove the supernatant by decanting, wipe off the excess moisture inside the tube with a laboratory wipe, and then resuspend the remaining pellets in the ultracentrifugation tube in 50 µL of 2x sample buffer to prepare the P2 EV fraction.
      6. Incubate the P1 and P2 EV fractions at 100 °C on a heat block for 10 min.
        NOTE: Do not shake the tubes after centrifugation at 20,000 × g and 110,000 × g to avoid accidentally discarding the remaining pellets. After tilting the tube to transfer the supernatant, maintain the tube's position to prevent the pellet from being immersed in the remaining supernatant again.
  2. Preparation of the cell fraction from cultured HeLa cells
    1. Day 5
      1. After transfer of the culture medium from the 10 cm plate into a 15 mL tube, wash the cells in the 10 cm dish with PBS and expose them to 2 mL of 0.25% trypsin and 1 mM EDTA solution at 37 °C with 5% CO2 and controlled humidity for 5 min.
      2. Add 8 mL of growth medium to the cells, then use a Pasteur transfer pipette with a 200 µL pipette tip to pipette the cells and prepare a single-cell suspension.
      3. Transfer the cell suspension into a 15 mL tube and centrifuge it at 1,000 × g for 10 min at 4 °C.
      4. Remove the supernatant by an aspirator, add PBS to the cell pellet, and then centrifuge at 1,000 × g for 5 min at 4 °C.
      5. Remove the PBS using an aspirator and sonicate the cell pellet in 1 mL of A68 buffer [10 mM Tris-HCl buffer, pH 7.5, 0.8 M NaCl, 1 mM ethylene glycol bis(β-aminoethyl ether)-N,N,N,N-tetraacetic acid (EGTA)] containing 1% sarkosyl.
      6. Measure the protein concentration of the cell lysate using a BCA protein assay kit.
      7. Mix 300 µL of the cell lysate with 100 µL of 4x sample buffer and incubate the mixture at 100 °C on a heat block for 10 min to prepare the cell fraction.

2. Immunoblotting analysis

  1. Separate equivalent amounts of proteins in the samples by SDS-PAGE18.
  2. Transfer the separated proteins onto polyvinylidene difluoride (PVDF) membranes.
  3. After transfer, block the membranes with the blocking agent for 20 min.
  4. Incubate the blocked membrane overnight with the indicated primary antibody in Tris buffer containing 10% (v/v) calf serum at RT.
  5. Wash the membrane with Tris buffer for 5 s and then incubate it with a biotin-conjugated secondary antibody at RT for 2 h.
  6. Wash the membrane with Tris buffer for 5 s and then incubate it with Tris buffer containing 0.4% (v/v) solutions A and solution B from the kit at RT for 1 h.
  7. Wash the membrane with PBS, and then incubate it with PBS containing 0.04% (w/v) diaminobenzidine, 0.8% (w/v) NiCl2·6H2O, and 0.3% (v/v) H2O2 for colorimetric detection of bands.
    NOTE: For the detection of signals, a chemiluminescence method is also acceptable.
  8. Digitize the image of the membrane by a scanner and subject it to densitometry analysis using Fiji.
    1. Open the digitized image using Fiji, and convert the RGB color image to an 8-bit image by clicking Image | Type | 8-bit.
    2. Click on the rectangle tool and adjust the size of the rectangle by dragging it to surround the bands. Identify the band to be analyzed by clicking Analyze | Gels | Select First lane.
    3. Position the rectangle on the second and the subsequent bands, and identify the bands for analysis by clicking Analyze | Gels | Select Next Lane.
    4. After recognizing the final band, measure the densitometry across the rectangle by clicking Analyze | Gels | Plot Lanes.
    5. Surround the signal area of the band with a straight line, click the wand tool, and click in the area to calculate the signal intensity of the band.

3. Analysis of the number of autophagosomes and autolysosomes

  1. Day 1
    1. Count the number of HeLa cells using a cell counter, and seed 1 × 105 HeLa cells expressing LAMP1-GFP and mCherry-LC3 on a 3.5 cm dish. Incubate the cells at 37 °C with 5% CO2 and controlled humidity for 24 h.
  2. Day 2 (optional)
    1. Perform the steps described in section 1.1.2 in 3.5 cm dishes.
  3. Day 3
    1. Discard the culture medium from the 3.5 cm dishes.
    2. Wash cells with PBS, expose them to 400 µL of 0.25% trypsin and 1 mM EDTA solution, and incubate at 37 °C with 5% CO2 and controlled humidity for 5 min.
    3. Add 1.6 mL of the growth medium to the cells, and pipette them with a Pasteur transfer pipette to prepare a single-cell suspension.
    4. Count the number of cells using the cell counter, and seed 1 × 104 cells on an 8-chambered coverslip. Incubate the cells at 37 °C with 5% CO2 and controlled humidity for 24 h.
      NOTE: Two wells of the chambered coverslip are prepared for control and STX6 knockdown cells, respectively, following DMSO or Baf treatment as described in section 3.4.2.
  4. Day 4
    1. Prepare the growth medium without phenol red (DMEM without Phenol Red, 10% FBS, 1% penicillin/streptomycin), containing either vehicle (DMSO) or 100 nM Baf dissolved in DMSO.
    2. Replace the culture medium with the medium without phenol red, containing either vehicle or 100 nM Baf, and incubate for 4 h.
      NOTE: To assess the effect of Baf on autophagosome and autolysosome numbers, prepare vehicle-treated cells as controls.
    3. Stain the nuclei with 0.33 µg/mL Hoechst 33342 for 30 min before observation.
    4. Conduct Live cell imaging using a 60x objective lens on a confocal laser microscope and capture ten different frames.
      1. Open the RGB merged image in Fiji, and split it into the respective red, green, and blue image components by clicking on Image | Color | Split Channels.
      2. Set a constant threshold for the red and green signals in each image by clicking Image | Adjust | Threshold for each experiment.
      3. Count the number of areas positive for red or green signals by clicking Analyze | Analyze Particles. Check the Summarize box, then click OK. Record the values from the Count to identify autophagosome- and lysosome-associated vesicles.
      4. To overlay the green image on the red image, set the transfer mode to AND by clicking Edit | Paste Control. Copy the green image and then paste it onto the red image to merge them, highlighting areas that are positive for both red and green signals.
      5. To identify autolysosome numbers, count the number of areas positive for both red and green signals by clicking Analyze | Analyze Particles. Check the Summarize box, click OK, and record the values in the Count section to identify vesicles associated with autophagosomes and lysosomes.
    5. Divide the total number of autolysosomes and autophagosomes by the total number of cells to calculate the number of autolysosomes and autophagosomes per cell.
      NOTE: Count at least 35 cells in each of the three independent experiments.

4. Analysis for omegasome formation

  1. Day 1
    1. Count the number of HeLa cells using a cell counter, and seed 1 × 105 cells on a 3.5 cm dish. Incubate the cells at 37 °C with 5% CO2 and controlled humidity for 24 h.
  2. Day 2 (optional)
    1. Perform the steps described in section 1.1.2.
  3. Day 3
    1. Prepare a single-cell suspension as described in steps 3.3.1-3.3.2.
    2. Count the cells using the cell counter, and seed 1 × 105 cells on a 3.5 cm dish. Incubate the cells at 37 °C with 5% CO2 and controlled humidity for 24 h.
  4. Day 4
    1. Mix 1 µg of pEGFP-C1-hAtg13, 3 µL of the DNA transfection reagent, and 100 µL of reduced serum medium in a low retention tube. Incubate the mixture for 20 min, then add it to the cultured medium.
    2. Incubate the cells at 37 °C with 5% CO2 and controlled humidity for 24 h.
  5. Day 5
    1. Trypsinize the cells as described in steps 3.3.1-3.3.2.
    2. Add 2.5 mL of the growth medium to the cells. Pipette the mixture using a Pasteur transfer pipette to prepare a single-cell suspension.
    3. Count the cells using the cell counter, and seed 1 × 104 cells on an 8-chambered coverslip. Incubate the cells at 37 °C with 5% CO2 and controlled humidity for 24 h.
  6. Day 6
    1. Follow steps 3.4.1-3.4.4 to conduct live cell imaging of the cells from step 4.5.3 using a confocal laser microscope. Capture ten different frames of images.
      1. Follow steps 3.4.4.1-3.4.4.3 to split the RGB merged images into the respective red, green, and blue image components, set a constant threshold for the green signals in each image, and determine GFP signal intensity. Record the values from the Total Area section to determine the signal intensity of GFP-ATG13.
      2. Divide the total signal intensity by the number of cells examined to calculate the signal intensity per cell.
        NOTE: Count at least 34 cells in each of the three independent experiments.

Results

As shown in previous studies, Baf treatment increased the levels of TSG101 (P1: P < 0.01, P2: P = 0.012, as determined by two-way ANOVA in EZR19) and LC3-II (P1: P < 0.01, P2: P < 0.01, as determined by two-way ANOVA in EZR19) in the EV-rich fraction. Notably, Baf treatment also increased the levels of STX6 (P1: P < 0.01, P2: P < 0.01, as determined by two-way ANOVA in EZR19) in the EV fraction (Figure 1A

Discussion

The immunoblotting study revealed LC3-II and TSG101 levels in the cellular fraction, the microvesicle-rich P1 EV fraction, and the exosome-rich P2 EV fraction. Live-cell imaging was used to examine autophagosomes, autolysosomes, and omegasomes, providing insight into whether STX6 knockdown influences autophagy. These combined results suggest that STX6 knockdown affects the release of LC3-II positive EVs, potentially linked to dysregulation of the autophagy pathway. A key advantage of this method is its ...

Disclosures

The authors declare that they have no conflicts of interest with the contents of this article.

Acknowledgements

This work was supported by funding to Y.T. from Japan Society for the Promotion of Science KAKENHI [Grant Number 23K06837] (Tokyo, Japan) and Takeda Science Foundation (Osaka, Japan). The authors appreciate Dr. David C. Rubinsztein (Cambridge Institute for Medical Research, Cambridge, UK) for supplying HeLa cells.

Materials

NameCompanyCatalog NumberComments
0.25 % Trypsin EDTAFujifilm Wako201-16945
10 cm DishThermo Fisher Scientific150464
15 mL TubeThermo Fisher Scientific339650
200 μL Pipette TipNippon GeneticsFG-301pipetting
2-MercaptoethanolNacalai Tesque21417-52a material for
sample buffer solution
3,3'-Diaminobenzidine TetrahydrochlorideNacalai Tesque11009-41a material for DAB solution
3.5 cm Dish Thermo Fisher Scientific150460
6 cm Dish TrueLineTR4001
Aluminium Block Thermostatic Baths (dry thermobaths)EYELA273860
AspiratorSANSYOSAP-102inhaling solution
Avanti JXN-30Beckman CoulterB34193
Bafilomycin A1AdipogenBVT-0252
Biotin-conjugated Goat Anti-rabbit IgG AntibodyVector Laboratories BA-10002nd antibody for immunoblotting
Biotin-conjugated Horse Antimouse IgG AntibodyVector Laboratories BA-20002nd antibody for immunoblotting
Blocking OneNacalai Tesque03953-95a material for immunoblotting
Bromophenol BlueNacalai Tesque05808-61a material for
sample buffer solution
Calf SerumcytivaSH30073.03
CanoScan LiDE 220CanonCSLIDE220Scanner
Centrifuge 5702 Reppendolf5703000039
Counting Slides Dual ChamberBio-Rad1450015Jcell counting
Digital Sonifier 450BRANSON
Dimethyl Sulfoxidenacalai tasque09659-14vehicle
DMEM High GlucoseNacalai Tesque08458-45culture medium
DMEM without Phenol RedNacalai Tesque08489-45culture medium
EGTADojindo 348-01311a material for A68 solution
ExcelMicrosoftversion 16.16.27satistical analysis
EZRReference No. 24version 1.68satistical analysis
FBSSigma173012Culture medium
FijiNIHImage analysis tool
GlycerolNacalai Tesque09886-05a material for
sample buffer solution
Hoehst33342Dojindo H342
Hydrogen PeroxideFujifilm Wako080-0186a material for DAB solution
Kimwipe S-200NIPPON PAPER CRECIA62011cleaning wipe
Low Retention TubeNippon GeneticsFG-MCT015CLBsiRNA and DNA transfection
LSM780 Confocal Laser MicroscopeCarl Zeiss
Monoclonal Mouse Anti-LC3 AntibodyMBLM186-31st antibody for immunoblotting
Nickel(II) Chloride HexahydrateFujifilm Wako149-01041a material for DAB solution
N-Lauroylsarcosine Sodium SaltNacalai Tesque20117-12
Optima XE-90 UltracentrifugeBeckman CoulterA94471
Opti-MEM I Reduced Serum MediumThermo Fisher Scientific31985-070siRNA and DNA transfection
pEGFP-C1-hAtg13Addgene22875
Penicillin/StreptomycinNacalai Tesque26253-84Culture medium
Pierce BCA Protein Assay KitsThermo Fisher Scientific23225
Polyclonal Rabbit Anti-PCNA AntibodyBioAcademia70-0801st antibody for immunoblotting
Polyclonal Rabbit Anti-syntaxin 6 AntibodyProteinTech10841-1-AP1st antibody for immunoblotting
Polyclonal Rabbit Anti-TSG101 AntibodyProteinTech28283-1-AP1st antibody for immunoblotting
Polyclonal Rabbit Anti-ULK1 AntibodyProteinTech20986-1-AP1st antibody for immunoblotting
Polyvinylidene Difluoride MembraneMillioreIPVH00010a material for immunoblotting
RR development core teamversion 4.4.1satistical analysis
RNAiMAXThermo Fisher Scientific13778siRNA transfection reagent
siRNA STX6Thermo Fisher ScientificHSS115604siRNA for transfection
Sodium ChlorideNacalai Tesque31320-05a material for Tris
buffer and A68 solution
Sodium Dodecyl SulfateFujifilm Wako192-13981a material for
sample buffer solution
SPARK Microplate ReaderTECAN
Stealth RNAi Negative Control Duplexes, Med GCThermo Fisher Scientific12935300siRNA transfection
SucroseFujifilm Wako193-00025a material for A68 solution
TC20 Automated Cell Counter with Thermal PrinterBio-Rad1450109J1cell counting
ThermobathTOKYO RIKAKIKAIMG-3100incubation
TransIT-293Mirus BioMIR 2700DNA transfection reagent
TransIT-LT1Mirus BioMIR2300DNA transfection reagent
Tris(hydroxymethyl)aminomethaneNacalai Tesque35406-75a material for Tris buffer, sample buffer and A68 solution
Trypan Blue Dye 0.40%Bio-Rad1450021cell counting
Ultra-Clear Open-Top Tube, 16 x 96mm Beckman Coulter361706collecting for the P1 EV fraction
Ultra-Clear Tube, 14 x 89mmBeckman Coulter344059collecting for the P2 EV fraction
Vectastain ABC Standard KitVector Laboratories PK-4000immunoblotting
Wash BottleAs One1-4640-02washing membrane
μ-Slide 8 Well Highibidi80806

References

  1. Tanaka, Y., Hasegawa, M. Profilin 1 mutants form aggregates that induce accumulation of prion-like tdp-43. Prion. 10 (4), 283-289 (2016).
  2. Mehta, P. R., Brown, A. L., Ward, M. E., Fratta, P. The era of cryptic exons: Implications for als-ftd. Mol Neurodegener. 18 (1), 16 (2023).
  3. Kawakami, I., Arai, T., Hasegawa, M. The basis of clinicopathological heterogeneity in tdp-43 proteinopathy. Acta Neuropathol. 138 (5), 751-770 (2019).
  4. Chatterjee, M., et al. Plasma extracellular vesicle tau and tdp-43 as diagnostic biomarkers in ftd and als. Nat Med. 30 (6), 1771-1783 (2024).
  5. Kasai, T., et al. Combined use of csf nfl and csf tdp-43 improves diagnostic performance in als. Ann Clin Transl Neurol. 6 (12), 2489-2502 (2019).
  6. Iguchi, Y., et al. Exosome secretion is a key pathway for clearance of pathological tdp-43. Brain. 139 (Pt 12), 3187-3201 (2016).
  7. Ding, X., et al. Exposure to als-ftd-csf generates tdp-43 aggregates in glioblastoma cells through exosomes and tnts-like structure. Oncotarget. 6 (27), 24178-24191 (2015).
  8. Mizushima, N., Levine, B. Autophagy in human diseases. N Engl J Med. 383 (16), 1564-1576 (2020).
  9. Sasaki, S. Autophagy in spinal cord motor neurons in sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 70 (5), 349-359 (2011).
  10. Ling, S. C., Polymenidou, M., Cleveland, D. W. Converging mechanisms in als and ftd: Disrupted rna and protein homeostasis. Neuron. 79 (3), 416-438 (2013).
  11. Nguyen, D. K. H., Thombre, R., Wang, J. Autophagy as a common pathway in amyotrophic lateral sclerosis. Neurosci Lett. 697, 34-48 (2019).
  12. Tanaka, Y., et al. Possible involvement of lysosomal dysfunction in pathological changes of the brain in aged progranulin-deficient mice. Acta Neuropathol Commun. 2, 78 (2014).
  13. Tanaka, Y., et al. Dysregulation of the progranulin-driven autophagy-lysosomal pathway mediates secretion of the nuclear protein tdp-43. J Biol Chem. 299 (11), 105272 (2023).
  14. Tanaka, Y., Ito, S., Suzuki, G. TDP-43 secretion via extracellular vesicles is regulated by macroautophagy. Autophagy Rep. 3 (1), (2024).
  15. Ratajczak, M., Ratajczak, J. Extracellular microvesicles/exosomes: discovery, disbelief, acceptance, and the future. Leukemia. 34 (12), 3126-3135 (2020).
  16. Tanaka, Y., Kozuma, L., Hino, H., Takeya, K., Eto, M. Abemaciclib and vacuolin-1 decrease aggregate-prone tdp-43 accumulation by accelerating autophagic flux. Biochem Biophys Rep. 38, 101705 (2024).
  17. Dingjan, I., et al. Endosomal and phagosomal snares. Physiol Rev. 98 (3), 1465-1492 (2018).
  18. Tanaka, Y., et al. Progranulin regulates lysosomal function and biogenesis through acidification of lysosomes. Hum Mol Genet. 26 (5), 969-988 (2017).
  19. Kanda, Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transpl. 48 (3), 452-458 (2013).
  20. Cookson, N. A., Cookson, S. W., Tsimring, L. S., Hasty, J. Cell cycle-dependent variations in protein concentration. Nucleic Acids Res. 38 (8), 2676-2681 (2010).
  21. Plate, L., et al. Small molecule proteostasis regulators that reprogram the ER to reduce extracellular protein aggregation. eLife. 5, e15550 (2016).
  22. Mizushima, N. The role of mammalian autophagy in protein metabolism. Proc Jpn Acad Ser B Phys Biol Sci. 83 (2), 39-46 (2007).
  23. Nanayakkara, R., et al. Autophagic lysosome reformation in health and disease. Autophagy. 19 (5), 1378-1395 (2023).
  24. Nozawa, T., Minowa-Nozawa, A., Aikawa, C., Nakagawa, I. The STX6-VTI1B-VAMP3 complex facilitates xenophagy by regulating the fusion between recycling endosomes and autophagosomes. Autophagy. 13 (1), 57-69 (2017).

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Explore More Articles

LC3 II ReleaseExtracellular VesiclesTDP 43 AccumulationNeurodegenerative DiseasesAutophagy RegulationALSFTLD TDPProgranulinHeLa CellsSiRNA TransfectionCulture MediumBafilomycin A1Cell CountingPrion like Spreading

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved